Optimizing First-Line and Sequential Therapy in Advanced NSCLC
Panelists discuss how biomarkers like PD-L1 guide first-line therapy in advanced non-small cell lung cancer (NSCLC), with higher expression favoring PD-1 inhibitors. Other factors like performance status and comorbidities also support their use. Post progression, PD-1 inhibitors are often used alone or in combination for subsequent lines of treatment.
Video content above is prompted by the following:
- What role do biomarkers like PD-L1 play in determining first-line therapy options for advanced NSCLC, and how does level of expression impact initial drug choice?
- What other patient characteristics influence initial treatment choices in advanced NSCLC, and how do they support using PD-1s as first-line options?
- Following disease progression on initial therapy, how frequently are PD-1 inhibitors used alone or in combination for subsequent lines of treatment?
Medicaid Expansion Linked To Timelier Lung Cancer Surgery and Access to High-Volume Hospitals
April 17th 2025New research shows that Medicaid expansion was linked to a 2.1% increase in timely lung cancer surgeries and a 2.8% rise in procedures at high-volume hospitals, highlighting how policy changes can impact cancer care access.
Read More
Chest X-rays Linked to Earlier Lung Cancer Detection and Improved Outcomes
April 7th 2025A new study in England shows a strong link between higher rates of chest x-ray referrals in general practice patients with symptoms, such as persistent cough, and earlier lung cancer diagnoses, along with improved outcomes.
Read More
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
March 18th 2025Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung cancer detection rates observed in those who followed through on these screenings.
Read More
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
March 7th 2025The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.
Read More
